INE 963
Alternative Names: INE-963; MMV-1582617; NVP-INE963Latest Information Update: 28 Jun 2024
At a glance
- Originator Novartis
- Class Antimalarials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Falciparum malaria
- Phase I Malaria
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Malaria(In volunteers) in United Kingdom (PO)
- 02 Mar 2024 Novartis Pharmaceuticals completes a phase I trial in Malaria (In volunteers, Monotherapy, Combination therapy) in United Kingdom (PO) (ISRCTN17232240)
- 23 Jan 2024 Phase-II clinical trials in Falciparum malaria (Combination therapy, In adolescents, In adults, In children, In the elderly) in Kenya, Ghana, Ivory Coast (PO) (NCT05750628)